Dr. Wanda M. Boote, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 374
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license 53607
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 374
- Services billed
- 1,908
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 471 | 293 |
| Destruction of precancer skin growth, 2-14 growths | 403 | 94 |
| Established patient office or other outpatient visit, 20-29 minutes | 291 | 206 |
| Destruction of precancer skin growth, 1 growth | 170 | 122 |
| Destruction of skin growth, 1-14 growths | 140 | 111 |
| Biopsy of related skin growth, first growth | 117 | 93 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 61 | 26 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 56 | 18 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 53 | 41 |
| Established patient office or other outpatient visit, 10-19 minutes | 45 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $304,210 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - A phase 2 randomized doubleblind placebocontrolled study to investigate the efficacy and safety of PF07275315 and PF07264660 in adult participants with moderatesevere atopic dermatitis
Pfizer Inc. - A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06136741 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136 - Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE)
Janssen Research & Development, LLC - M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc. - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.